Cancer Immunotherapy Animation
SCIENTIFIC ANIMATION | Corporate communications and visual continuity
Gradalis’ Vigil® Platform is a fully personalized, patient-specific cancer immunotherapy. The Vigil® Platform is indicated for patients with advanced solid tumors and is currently being developed for the treatment of ovarian cancer and breast cancer. The Vigil® Platform uses the patient’s cancer cells to create a personalized cancer immunotherapy that activates the patient’s own T-cells to fight their cancer cells.
This mechanism of action (MoA) animation explores this platform using eye-catching visuals, showcasing how the innovative therapy works. The treatment involves surgically removing tumor tissue from the patient. Cancer cells from the tumor are then genetically modified and reintroduced back into the patient. These gene modifications help activate the immune system to detect and kill any cancer cells that may remain locally and in circulation.
The medical animation can be found on the Gradalis website on the product page. A looping clip created from animation content is also featured on the website.
Are you interested in seeing how our award-winning medical animation can help you?
Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.
TESTIMONIALS
‘‘Extremely happy, everybody was great on the team. They answered all our questions and made it look easy. The end result is perfect. ’’
Executive Coordinator, Cellectar Biosciences
‘‘The presentation was dramatically enhanced by the video, which looked fantastic on the big screen. Thank you and the entire Random42 team for your excellent work and for getting the final edition to me in time for the conference. All very much appreciated! ’’
President and CEO, Vallum Corporation
‘‘The quality of the work produced by Random42 sets them apart and helps us quickly tell our scientific story more clearly. The high-quality production value is bolstered by their depth of knowledge. Together, that helps us tell the story of a complex disease and cell-based treatment and make it understandable to professionals and laypeople alike.’’
CEO, Brainstorm Cell Therapeutics
‘‘Working with the Random42 team was a seamless collaboration, where they exhibited great project management skills, clear & thoughtful communication, and delivered high-quality work that was visually appealing. Our team was impressed with the final products!’’
Medical Affairs, Phathom Pharmaceuticals
